1 June 2021: Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study
10 March 2021: VISION-DMD Releases White Paper on returning individual clinical trial data to participants
3 March 2021: Santhera and ReveraGen BioPharma Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy
17 November 2020: ReveraGen BioPharma receives $3.3 Million NIH grant for NDA preparations for Vamorolone
02 June 2020: ReveraGen BioPharma completes 2.5 years vamorolone treatment of 41 Duchenne muscular dystrophy boys.
17 October 2019: Vamorolone Designated Promising Innovative Medicine (PIM) for treatment in Duchenne muscular dystrophy
11 October 2019: VISION-DMD announces all UK clinical trial sites now open for recruitment for Phase 2b vamolorone study in Patients with Duchenne Muscular Dystrophy
5 October 2019: Top-line data of 18-month vamorolone treatment of Duchenne muscular dystrophy patients shows continued improvement of symptoms with reduction in corticosteroid safety concerns
August 2019: Vamorolone treatment of Duchenne Muscular Dytrophy patients leads to improvement in motor function
August 2018: First Patient Enrolment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy
June 2018: Vamorolone Phase 2 top line press release
February 2018: ReveraGen BioPharma initiates VISION-DMD Phase 2b Study for Treatment of Duchenne Muscular Dystrophy
March 2017 : Vision-DMD update: ReveraGen BioPharma Receives FDA Fast Track Designation for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
September 2016 : ReveraGen BioPharma Inc initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy
